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SOMMAIRE 
Le sujet de cette étude est la libération contrôlée de substances actives de 
grandes masses moléculaires: protéines et peptides. L'inconvénient commun de ces 
médicaments est leur administration par injection. Des micro gels ont été synthétisés en 
tant qu'excipients potentiels administrés par voie orale afin de protéger les protéines 
thérapeutiques contre les enzymes digestives, la dénaturation provoquée par le suc 
gastrique et pour permettre la libération prolongée de ces grosses molécules peu 
perméables directement aux muqueuses intestinales. 
Ces microgels sont formés d'un réseau de copolymères de poly(acide acrylique) 
entrecroisés de diméthacrylate d'éthylèneglycol et greffées de copolymères séquencés -
poly( oxyde d'éthylène)- poly( oxyde de propylène). Ils sont synthétisés par une 
copolymérisation entrecroisée radicalaire en une étape relativement simple.(ll) La 
formulation est simplement constituée d'un mélange à sec de microgels avec la protéine 
lyophilisée qui est ensuite directement comprimé. Les microgels répondent au 
changement du pH de l'environnement: ils restent intact en conditions acides et se 
gonflent en pH neutre. Ils possèdent des propriétés mucoadhesives et sont non irritants.(6, 
8, 10) Ces caractéristiques font de ces microgels de excipients potentiels pour la livraison 
orale des protéines thérapeutiques. 
La première section de cette thèse est un examen des différentes formes de 
libération contrôlée. La section expérimentale décrit la synthèse de trois micro gels et leur 
caractérisation par une variété de méthodes sous forme de particules sèches aussi bien 
II 
que dans un milieu aqueux. Dans cette partie, des micro gels sont formulés avec de 
l'albumine lyophilisée de sérum de boeuf utilisée comme protéine modèle. La capacité de 
chargement de ces micro gels a été évaluée. Des profils de libération de micro gels en 
conditions imitant le milieu gastro-intestinale sont comparés entre eux et aux deux 
excipients généralement utilisés: lactose et Carbopol. Les résultats de l'étude de libération 
de protéines ont été interprétés par la méthode de Ritger et Peppas. 
MOTS CLES: microgels, libération orale contrôlée, protéines thérapeutiques 
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SUMMARY 
The subject of this study is controlled release of proteins and peptides. Common 
disadvantages of these medications are their administration by injection. Microgels were 
synthesized as potential excipients for oral delivery of therapeutic proteins for their 
protection from the digestive enzymes and the denaturation caused by the stomach acid 
and to provide prolonged release of the se large and poorly permeable molecules directly 
to the intestinal mucosa. 
Microgels are composed of copolymers of ethylene glycol dimethacrylate 
crosslinked network of poly(acrylic acid) with grafted block-copolymer chains of 
poly(ethylene oxide)-poly(propylene oxide), which are synthesized by a relatively 
straightforward one-step free-radical crosslinking copolymerization.(ll) The microgels 
respond to environmental pH change: they collapse in acidic conditions and swell at 
neutral pH. They are proven to possess mucoadhesive properties and are non-
irritating.(6, 8, 10) The drug product is formulated by simple blending of dry microgel 
with lyophilized protein and directly compressed. 
The theoretic part of this thesis is a review of the different controlled-release 
forms, therapeutic proteins and their delivery systems. The experimental part describes 
the synthesis of three microgels and their characterization by a variety of methods alone 
as well as in formulations with a model protein, bovine serum albumin, in conditions 
mimicking the gastro-intestinal tract. The results of prote in release study were interpreted 
by the method of Ritger and Peppas. 
KEY WORDS: microgels, therapeutic proteins, controlled oral delivery, 
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THEORETIC PART 
1. CONTROLLED DRUG RELEASE 
1.1. Introduction 
Controlled-release products are formulated to release drug's active ingredient 
gradually and predictably over a I2-hour to 24-hour period. These formulations 
compared with the immediate-release drugs might provide potentially greater 
effectiveness in the treatment of chronic conditions through a more consistent delivery 
of the medication: reduced side effects, greater convenience and higher levels of patient 
compliance due to a simplified dosage schedule. 
The administration of a conventional or immediate-release dosage form 
provides rapid absorption initially with drug concentration in patient's plasma reaching 
peak maximum rapidly followed by a decrease in drug level due to progressive 
elimination of active pharmaceutical ingredient (urinary or other excretion, metabolism, 
degradation, etc). 
With conventional fast release drug products, in order to maintain plasmatic 
drug concentration within therapeutic range in order to provide effective therapy it was 
recommended to multiply the drug administrations. This type of medication has 
demonstrated numerous disadvantages such as fluctuation "peak and valley" of 
plasmatic concentration of the drug, adverse side effects (if maximum plasma 
concentration reaches toxic level) or lost of therapeutic effect, (plasma concentration 
decreasing rapidly, falling lower then the minimum effective concentration if the active 
pharmaceutical ingredient has a short half-life) 
1 
1 2 3 4 
Frequency of Usage 
Figure 1: Blood drug concentration levels after administrating multiple doses of 
conventional dosage form (An) vs. a single dose of a long-acting controlled-
release drug delivery system (B) (courtesy ofNoveon) 
Thus once-daily dosing carries significant benefits in terms of convenience and 
compliance. The potential also exists to improve the side-effect profile and enhance the 
overall efficacy of existing drugs. 
It is important to control drug release in such a way that drug concentration in 
plasma is constant and the intervals between drug administrations are increased. The 
kinetics of dissolution of the active pharmaceutical ingredient might be modified by 
alteration of physical properties such as particle shape or type of polymorph. Drug 
release might be also controlled by adjustment of the dosage form to the requirements 
of the particular active pharmaceutical ingredient delivery. 
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Figure 2: Blood drug concentration profiles of different controlled-release dosage 
forms 
1 - Conventional form 
3 Extended release form 
5 - Sustained release form 
1.2. Controlled-Release Terminology 
1.2.1. Controlled release 
. 2 Pulsatile release form 
4 - Delayed release form 
Controlled drug delivery systems usually have the same route of administration 
as a conventional form. However, it delivers the drug at a predetermined rate and/or to 
a specifie location according to the need of the body and the disease states over a 
definite time period.(38) 
3 
1.2.2. Extended release 
Extended-release systems include any dosage form that maintains effective 
therapeutic blood or tissue levels of the drug for a prolonged period. If the system can 
provide sorne actual therapeutic control of drug release in the body, whether it is 
temporal, spatial or both, it is considered a controlled delivery system. Extended release 
is not equivalent to controlled-release.(23) 
1.2.3. Modified-release 
This term is defined in the European Pharmacopoeia as a modification of the 
rate or place at which the active substance is released. Modified-release products coyer 
a wide range of release models, the principal types of which would include "delayed 
release" and "prolonged release" products.(3) 
1.2.4. Delayed release 
Delayed-release systems are either repetitive, intermittent dosing of a drug 
form one or more immediate-release units incorporated into a single dosage form, or an 
enteric delayed-release system. Examples of delayed-release systems include repeat-
action tablets and capsules, and enteric-coated tablets where timed release is achieved 
by a barrier coating.(23) The European Pharmacopoeia de fines delayed release form as 
a modified release product, in which the release of active substance is delayed for a 
finite "lag time", after which release is unhindered. [e.g. enteric coated or "Gastro 
4 
resistant" (Ph.Eur.) oral tablets or capsules which remain intact in the stomach and only 
disintegrate in the higher pH of the small intestine] 
1.2.5. Prolonged release 
Prolonged-release form is a product in which the rate of release of active 
substance from the formulation has been reduced, in order to maintain therapeutic 
activity over a prolonged period of time, to reduce toxic effects or for sorne other 
therapeutic purpose.(52, 18, 21) 
1.2.6. Site-specifie release 
Site-specific release refers to targeting of a drug to a certain biologicallocation. 
The drug is adjacent to or in the diseased organ or tissue. This system satisfies the 
spatial aspect of drug delivery requirement and is also considered controlled drug 
delivery system.(23) 
2. FUNDAMENT AL ASPECTS OF CONTROLLED RELEASE 
2.1. Diffusion 
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In this equation 
J 
S 
D 
dc/dx 
is the flux of drug in the direction of decreasing concentration 
(amountlarea-time; mol/cm2 .sec) 
is the mass of the drug released at the time t (mol) 
is the surface of diffusion (cm2) 
is the diffusion coefficient of the drug (cm2/sec) 
is the concentration gradient (mol/cm4) 
The negative sign of the drug flux simply demonstrates that the vector of J is 
opposite to the vector of the concentration gradient. 
This first law of diffusion is used to derive the equations applièable to diffusion-
controlled reservoir drug systems, which are characterized by the constant 
concentration gradient (steady state). 
In matrix systems the concentration gradient on contrary varies with time. In 
this model it is assumed that the solid drug dissolves from the surface layer of the 
dosage form first; when this layer becomes exhausted of drug, the next layer begins to 
be depleted by dissolution and diffusion through the matrix to the bulk solution. The 
6 
interface between the region containing dissolved drug and that with dispersed drug 
moves into the interior as a front. 
Fick's second law of diffusion is applied to non-steady or continually changing 
diffusion state: 
(eq.2) 
Where··· 
It is important to stipulate that both Fick's laws in the forms of equation 1 and 2 
respectively are not applicable if diffusion coefficient D is not constant at unvarying 
temperature. 
2.2. Solute diffusion mechanism 
Considering that distribution of an active pharmaceutical ingredient within the 
pol ymer matrix is uniform, the release mechanism can be explained as follows: water 
or another biological fluid, while in contact with a pol ymer, penetrates into the material 
progressively dissolving the active pharmaceutical ingredient, which diffuses toward 
the exterior via a porous network or through intermolecular space. The type of the 
7 
transfer largely depends on a polymer state (glassy or rubbery).(61) According to the 
temperature, the polymers are in glassy state if T < Tg or are in rubbery state if T > Tg, 
where Tg is the temperature of glass transition and T is the temperature of the polymer. 
The macromolecular chains of the pol ymer, when in rubbery state, move 
constantly creating large spaces or "pockets", which are permeable for solvent 
molecules. (Fig. 3) 
" 
(a) 
Figure 3: Swelling of a hydrophilic pol ymer 
1 polymer in glass y state 
2.3. Three types of the transport 
2.3.1. Fickian type transport or "case 1" 
(bl 
2 - polymer in rubbery state 
This type of the transport is applicable to rubbery state polymers, where 
macromolecular chains are very flexible and adjust rapidly to the presence of solvent 
molecules(61) when the diffusion velocity of solvent molecules is significantly lower 
than the relaxation of macromolecular chains. This is a Fickian type also known as 
"case 1" diffusion. 
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The quantity of diffused substance Mt at the time t might be expressed as 
following: 
Where 
(eq.3) 
The diffusion velocity, derived from the previous equation is: 
dM/dt= 112. k. fOS (eq.4) 
k is a constant, which depends on form of the polymer and the 
diffusion coefficient. 
, kthethrit: (sec) i' 
2.3.2. "Case II'' type diffusion 
This type of transport is characteristic to polymers in glassy state where the 
relaxation of macromolecular chains is significantly lower then the velocity of solvent 
molecules diffusion.(61) 
The quantity of adsorbed or desorbed solvent is expressed as follows: 
(eq.5) 
And the velocity of diffusion is respectively: 
dM/dt=k (eq.6) 
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2.3.3. "Case III" type diffusion 
Non-Fickian or "anomalous" diffusion is observed when the velo city of solvent 
molecules diffusion and the relaxation of the macromolecular -chains are of the same 
order. This type of the transport is in between the "case 1" and the "case II''. The 
quantity of adsorbed or desorbed solvent is given as: 
(eq.7) 
And the velocity of diffusion is respectively: 
dM/dt=n.k.f-1 (eq.8) 
It has to be noted that the diffusion follows the Fick's law (case 1) if n=0.5; if 
the value of the parameter n is in between 0.5 and 1, then the process is anomalous 
(case III). However, when this parameter is' close to one, the diffusion of the solute 
within the polymers approaches the zero order kinetics (casé II). Table 1 demonstrates 
the three cases.( 48) 
Graphie presentation of the theory of solute diffusion (release) from the 
polymers for three types of diffusion is shown in the Figure 4.(33) 
10 
Parameter "n" Diffusion type , Diffusion velocity 
(dM/dt) 
0.5 Fickian diffusion (case I) (Ifl. 
0.5 < n < 1 Anomalous diffusion (case III) f-I 
i 
1 "Case II'' type diffusion Constant 
1 1 
n>l "Super-case II'' type diffusion tn- l 
Table 1: Diffusion type and the kinetic parameter "n" 
Figure 4: Demonstration of Fickian (a), anomalous (h) and "case II'' (c) types of 
diffusion. 
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3. CONTROLLED-RELEASE SYSTEMS CLASSIFICATION 
Systems of the release might be sorted in four major classes according to the 
nature of the drug transport.(34) 
3.1. Diffusion-controlled systems 
These systems are more frequently studied and utilized. There are two diffusion 
modes: the active pharmaceutical ingredient might diffuse through the polymer 
structure (within the intermolecular space) as well as from a porous network filled with 
the solvent. There are two major types of formulation: reservoir and matrix. 
3.1.1. Reservoir systems 
In reservoir systems, the active pharmaceutical ingredient is coated with 
swellable or non-swellable polymerie film. The drug might be in solid form, in solution 
or . concentrated suspension as weIl as mixed with another solid excipient. The 
polymerie membrane controls the drug release. In general, these systems include coated 
tablets and granules, macro and microcapsules, liposomes and hollow fibers. Fick's 
equation characterizes the diffusion of the drug: 
dQ/dt = D.S.A.(CrCJJ/X (eq.9) 
Where 
dQ/dt is amount of active pharmaceutical ingredient (g) diffused per 
unit oftime (sec) 
D is a diffusion coefficient (cm2/sec) 
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s IS partition coefficient of the substance between the coated 
dosage form and the aqueous phase of the gastro-intestinal tract 
is a membrane surface (cm2) 
IS a concentration of solution saturated with active 
. pharmaceutical ingredient (g/cm3) 
is concentration of APIon GI tract side (g/cm3) 
x is a membrane thickness (cm) 
In this case, the released drug is characterized by "zero order" kinetics as long 
as API within the film coated compartment is highly saturated since the diffusion 
coefficient, the partition coefficient, the membrane thickness and the surface area are 
constant.(32) The rate of release may be modified by changing the thickness of 
membrane, the surface area or the diffusion coefficient of API. For example, 
permeability of a membrane might be modified by adding more hydrophobie or 
hydrophilic polymers, like poly-ethylene oxide and poly-propylene oxide block 
copolymers or Pluronics®. 
A major advantage of these systems is the possibility to obtain "zero order" 
release, which is problematic with other dosage forms. 
There are a few disadvantages to the reservoir systems such as: accidentaI 
damage of a dosage form coating might cause dumping of the API contained in the 
reservoir.(19) "Zero order" is obtained only for the period of time when API inside the 
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coating is at high saturation, this varies with solubility. The manufacturing of reservoir 
dosage forrns is still relatively expensive due to the technology requirements. 
3.1.2. Matrix systems 
In the matrix systems the drug is uniforrnly distributed within the solid insoluble 
polymer excipient. The API embedded in this excipient network provides extended 
release.(32) The matrix may also be constituted of hydrophilic substances, which, when 
is in contact with water, forrn a gel. 
The solvent penetrates into the system and progressively dissolves the API, 
which then diffused to the exterior through the porous network or interrnolecular space. 
A matrix may be forrned by the evaporation of the solvent from a polymer 
solution with dispersed or solubilized API. The polymer should be hydrate d, dissolved 
or disintegrated before the drug is dissolved and diffused from the polymeric matrix. 
These systems are characterized by slow release. The API is not chemically bound to 
the polymer. The drug is active and is not modified. 
Based on the nature of the pol ymer, matrix system may be classified as 
hydrophilic, inert or lipid. 
3.1.2.1 Hydrophilic matrixes 
These matrixes include a cellulose-derived polymers (hydroxyl-propyl 
methylcellulose and carboxyrnethylcellulose sodium salt) and vegetable-derived 
polysaccharides (alginates, agar-agar and modified amidons) or polyrners of animal 
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origin (gelatin and chitosane) as weIl as synthetic materials (polyviny 1 acetate, 
polyethylene glycol and polyacrylic acid). 
Polysaccharide hydrophilic polymers are often used in oral extended-release 
formulations. Compared to inert and lipoid matrixes they are simple to formulate, might 
be loaded with API up to 80% w/w, are relatively inexpensive and versatile as they can 
be formulated with varied types of API.( 40) 
At the releasing contact area of a hydrophilic matrix, sorne amount of the drug 
is released instantly (burst effect), then hydratation of the gel-forming agent leads to the 
fast formation of progressively increasing gelated barrier on the surface of the dosage 
form. The API diffuses through this gelated barrier in to the aqueous surrounding. The 
release velocity progressively decreases as a function of the square root of the time.(36) 
For example, drug release from a flat disk-shaped matrix might be estimated by this 
form of the Hugichi equation (29): 
Where 
M = -VIC •. (2.A-CJ.D.tj (eq.lO) 
M amount of drug released from the unit of surface during the time 
t (g/cm2) 
solubility of the drug in the matrix (g/cm3) 
A concentration of the drug (g/cm3) 
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t time(sec) 
D diffusion coefficient (cm2/sec) 
3.1.2.2 Inert matrixes 
Polymers used for inert matrixes are of a porous structure, non-toxic and 
chemically neutral to the API (polyvinyl' chloride, polyethylene, ethylcellulose, silicone 
etc.). 
In these dosage forms formulated drug dissolves and diffuses through the 
pores. The release is thus controlled by the porous structure. The rate of release may be 
modified by the alteration of a network pores' diameter,(53) shape and the dimensions 
of the dosage form.(3) 
The amount of released API is proportional to the square root of time. This 
matrix system release might be characterized by the solubility of the API, diffusion 
coefficient, porosity and tortuosity of the dosage form. 
Higuchi proposed a following mathematical model for a plane surface (29): 
Mt = S . ...JID.é.C~(2Cu-é.CJ.t/rJ (eq.l1) 
Where 
Mt amount of API released at the time t (g) 
S surface of a dise (cm2) 
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D API diffusion coefficient (cm2/sec) 
li matrix porosity (sec/cm) 
CS API solubility in water (g/cm3) 
matrix tortuosity (cm) 
Co concentration of API at the time zero (g/cm3) 
Inert matrixes are relatively simple to formulate and manufacture by dry 
blending and direct compression. The release of API from these matrix systems is 
independent of the exterior conditions. 
3.1.2.3 Lipid matrixes 
A variety of biodegradable excipients is used to formulate these matrixes: 
natural and synthetic waxes, fatty acids and their esters, fatty alcohols, hydrogenised 
oils, etc. The API may be released through diffusion and through erosion of the matrix 
by enzymatic hydrolysis of the lipids.(13) 
Drug release from lipid matrixes depends on digestive enzyme composition of 
the stomach fluids.(20) The amount of released drug substance is proportional to the 
quantity of the excipient hydrolyzed by the enzymes.(S1) 
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3.2. Solvent-controlled systems 
3.2.1. Osmotically controlled systems 
The majority of the se systems were developed by ALZA Corporation. In the 
relatively simple dosage form, OROS®,(59) an osmotically active API in a core (drug 
substance blended with sodium or potassium chloride as osmosis agent) is surrounded 
by semi-permeable membrane which is permeable only to water. The drug substance is 
pumped out of the system through laser-drilled orifice at the same rate as the volume of 
water entering into core multiplied by drug concentration. The "zero order" drug 
release is controlled by the osmotic properties of the dosage form, surface, thickness 
and permeability of a membrane. 
Drug solution < Laser-drilled 
'.' . l.L,Orffice. '., 
i~'I)'~IoiIIoiII~~'" .,.. ..... ~ ... IIooW~ ... ' ... 
':. Water 
, ,'::':-,,', 
• 
'. Osmotically active drug 
Rigid semi-permeable membrane 
Figure 5: Simple osmosis-controlled oral system (OROS®) (courtesy of ALZA 
Corporation) 
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3.2.2. Swelling controlled systems 
Swelling controlled systems are composed of a slowly hydrating polymer 
loaded with a drug substance that allows controlled permeation of the solvent.( 46) 
Limited swelling depends in general on the nature of a pol ymer and in particular on the 
degree of cross-linking. At the initial phase, the polymer is in glassy form when API 
diffusion is nearly zero due to very low diffusion coefficient. Solvent permeation 
initiates phase transition to the rubbery state at the swelling interface. The drug 
substance diffuses through the rubbery portion toward the aqueous exterior.(35) Drug 
release is controlled by the progressive move of the permeation front. 
Drug substance 
••• 
•• •• •• • ••• 
• •• 
• • 
Glossypolymer 
Rubbery section 
Figure 6: Simplified release mechanism of a limited swelling matrix system 
Developed by ALZA Corporation, the OROS® Push-Pull™ system IS 
controlled by both: osmosis and swelling. A push compartment containing swellable 
polymer material is placed inside semi-permeable membrane provides delivery of a low 
solubility drug substance in a form of fine suspension.( 43) 
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Figure 7: Schematic representation of the OROS® Push-Pull™ system. 
(Courtesy of ALZA Corporation) 
3.3. Chemically controlled systems 
3.3.1. Biodegradable systems 
Matrix technology is more often applied to biodegradable systems rather than 
to reservoir. However, the latter exists mostly as skin patches and microcapsules. In the 
case of matrix technology the system erodes gradually releasing the APL In. reservoir 
systems the polymer coating may de grade after complete drug substance release. 
Heller categorized biodegradable systems in three major groups based on their 
bio-erosion mechanism (1,27): 
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--------------------------------- -_ ..... -
a. Insoluble polymers with biodegradable main chain, which breaks into 
smaller soluble molecules when hydrolyzed 
1 
X 
b. Hydrolysis of cross-linking bonds 
1 
x 
1 
x x 
x 
1 
c. Insoluble polymer, which IS dissolved after their side chains are 
hydrolyzed, ionized or protonated 
1 1 1 
A B c 
B--C = hydrolysis, ionization or protonation 
For the majority of the biodegradable systems release, kinetics is the result of 
a combination ofboth - diffusion of drug and erosion of the polymer.(56) 
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J 
(b) Diffusion + erosion 
Drug 
release 
Time 
(a) Diffusion 
Figure 8: Theoretic drug release profile for diffusion-controlled (a) and controlled by 
diffusionlerosion (b) systems 
3.3.2. Grafted chains systems 
In these systems pharmaceutically active substance that chemically bound to a 
polymer structure is released by hydrolysis or enzymatic cleavage. The polymer 
backbone itself might be biodegradable. Drug substance might be attached directly to 
the polymer backbone or through a linking agent, which would affect the hydrophilic 
properties of the system and eventually drug release rate.( 47) 
Covalent bond Drug substance 
·rrrI··· 
HYdr~IYSiS or' / . 
Enzyme activity 
Figure 9: Schematic representation of grafted chains system 
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3.4. Systems activated by magnetic fields 
These systems are characterized by having a drug substance and small 
magnetic particles uniformly distributed in the polymer matrix. The dosage form, when 
placed into aqueous milieu, releases active pharmaceutical ingredient in accordance 
with c1assic mechanism of diffusion described in respective section. However, drug 
substance is released at significantly higher rate when exterior oscillating magnetic 
fields are applied. 
This phenomenon might be explained by increase of the matrix pores due to 
attraction and repulsion between magnetic particles. The latter allows the drug 
substance to be released faster. 
3.5. Bioadhesive delivery systems 
Bioadhesion is a complex phenomenon related to the ability of sorne natural 
and synthetic macromolecules to adhere to biological tissues. If a biological substrate is 
a mucus membrane, bioadhesive interactions occur primarily with the mucus layer and 
this process is referred to as mucoadhesion. The bonds involved are more likely to be of 
secondary chemical nature, combined with physical entanglement of polymer chains. 
The process is a reversible one, where the mucoadhesive detachment is caused either by 
the breakage of low energy bonds or by the physiological process of mucus 
turnover. (58) 
Mucoadhesive controlled release dosage formulations have gained considerable 
attention due to their ability to adhere to the mucus layer and release the loaded drug in 
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a sustained manner. By using these dosage forms, contact time with the mucus surface 
increases, which results in an increased drug retenti on at the site leading to improved 
therapeutic efficacy, especially for large molecules like proteins. Diverse classes of 
polymers have been investigated for potential use as mucoadhesives. These include 
well known mucoadhesive polymers such as poly(acrylic acid), hydroxypropyl 
methylcellulose and poly(methylacrylate) derivatives, as weIl as naturally occurring 
polymers such as hyaluronic acid and chitosane.( 60) 
4. THERAPEUTIC PROTEINS AND THEIR DELIVERY 
Therapeutic proteins are promising alternative to drug small molecules. 
Protein based drugs have demonstrated extraordinary selectivity and lower risk of 
undesired side effects with the administration of micro gram amounts per daily dose. 
Unlike other medicines, they are not synthetically manufactured, and are usually 
produced through microbial fermentation or by mammalian cell culture. They are also 
more complicated, time-consuming and expensive to produce than synthetic drugs.(60) 
4.1. Marketed protein based drug products 
Currently therapeutic proteins are used to relieve patients suffering from 
<i various cancers (monoclonal antibodies, interferons), heart attacks, strokes, cystic 
fibrosis (enzymes, blood factors), diabetes (insulin), anemia (erythropoietin) and 
hemophilia (blood clotting factors). Leading protein based drug products on the market 
today are Procrit® and Epogen® for anemia treatment from Johnson & Johnson and 
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Amgen respectively, Intron A ® and Peg-Intron® for hepatitis from Schering-Plough and 
few others.(60) 
The delivery of these protein based drug products is currently performed 
through intravenous or subcutaneous injections, which is inconvenient for patients, 
increases treatment cost, and bears aU the risks related to this mode of drug 
administration. 
4.2. Alternative ways of protein and peptide administration 
Varietyof approaches has been developed as alternative delivery systems for 
therapeutic proteins and large peptides in order to avoid injections. Oral and nasal 
administration, pulmonary inhalation, implants and other pathways have been studied 
by different research groups and pharmaceutical companies for the deli very of large 
drug molecules. 
Pulmonary inhalation, which does not require deep lung delivery was applied 
by Syntonix Pharmaceuticals to develop a novel formulation for Interferon-beta therapy 
for multiple sclerosis.(60) 
Nasal formulation of leuprolide (ChiSys-Leuprolide™), a gonadotropin-
releasing hormone agoni st that is used in the treatment of hormone-responsive cancers 
and control of ovarian stimulation in in vitro fertilization is undergoing phase II clinical 
trial sponsored by West Pharmaceutical Services, Inc.(60) 
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A number of the research groups work currently on implant delivery systems 
for prolonged release oftherapeutic proteins and peptides. Kajihara et al. has developed 
subcutaneous silicone implant covered with human serum albumin or interferon in 
order to achieve a zero-order release of protein drug for 30-100 days without significant 
initial burst.(30) In another implant system, bovine serum albumin was loaded into 
poly(D,L-lactic-co-glycolic acid) micropartic1es coated with poly(vinyl alcohol) and 
incorporated into PLGA tissue-engineered scaffolds. These tissue-engineered implants 
have provided long-term controlled release of the protein.(28) 
The main barriers to oral administration of therapeutic proteins are the delicate 
physiochemical properties of protein-based drugs, which are sensitive to digestive 
enzymes and may be denatured by stomach acid before absorption. Another issue is the 
size of therapeutic proteins.(41) Being large and bulky molecules and characterized by 
poor permeability through intestinal mucosa, they require long time to be adsorbed with 
direct contact to the mucosa in order to traverse the intestinal tissue. 
Orally administered enzyme products are being developed by Altus 
Pharmaceuticals. In these protein based drug products an active ingredient is cross-
linked and crystallized in order to protect the substance from degradation in the 
stomach.(60) 
Marschutz M.K. et al. prepared matrices of the mucoadhesive pol ymer 
sodium carboxymethylcellulose with the covalently bound Bowman-Birk enzyme 
inhibitors and elastatinal enzyme inhibitors for the protection of embedded insulin from 
degradation by the luminally secreted serine-proteases. These oral drug-carrier matrices 
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have provided up to 80% of insulin recovery after one hour of treatment in artificial 
intestinal fluid.(39) 
Peppas N.A. and Foss A.C. et al. have developed nanospheres of crosslinked 
networks of methacrylic and acrylic acids grafted with poly( ethylene glycol) for use as 
oral insulin delivery devices.( 49) It was determined using photon correlation 
spectroscopy that nanospheres increased ten times in diameters in response to pH 
change from 2.0 to 6.0. Loading of insulin up to 7% w/w into the copolymers was 
achieved by partitioning from concentrated insulin solutions. In vitro studies have 
confirmed that insulin was protected at pH lower then 3.0 and released at pH 5.5. 
Animal studies were performed to investigate the abilities of insulin-Ioaded copolymer 
samples to influence the serum glucose levels of rats. In studies with diabetic rats, the 
serum glucose level was lower than control values for the animaIs that received the 
insulin-Ioaded copolymers and lasted for at least 6 h. The insulin loaded copolymer 
nanospheres caused a significant reduction of serum glucose with respect to that of 
control animaIs. 
Therefore oral administration of therapeutic proteins is considered to be an 
advantageous alternative to injections and may be applied to novel therapeutic proteins 
and peptides as well as to already marketed products. 
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5. MICROGELS, NOVEL EXCIPIENTS FOR PERORAL DELIVERY AND 
CONTROLLED RELEASE OF THERAPEUTIC PROTEINS 
In the past thirty years, work on hydrogels based· oncrosslinked copolymers 
has led to the establishment of a number of controlled release products for 
pharmaceutical agents.(24, 25, 62) Poly(acrylic acid)-based resins have been a subject 
of numerous drug master files with the U.S. FDA.(15) 
In this study microgels as copolymers of poly(acrylic acid) network 
crosslinked by ethylene glycol dimethacrylate with grafted block-copolymers chains 
(poly(ethylene oxide)-poly(propylene oxide) or poly(propylene glycol)) were 
synthesized in order to be studied as a potential system for oral delivery of therapeutic 
proteins. 
5.1. Grafted block copolymers 
Three block copolymers with different hydrophile-lipophile characteristics were 
selected to be cross-linked to microgels. Pluronic® is a trade name for group of 
poly(ethylene oxide)-poly(propylene oxide) (PEO-PPO-PEO) block copolymers 
approved by the FDA as food additives and pharmaceutical ingredients. (2) Pluronic® 
L92 is hydrophobic with a molecular weight of 3650 Da, Pluronic®F127 is relatively 
hydrophilic and has a molecular weight about three times higher. The hydrophile-
lipophile properties of Pluronics® depend on their composition (Fig.10): Pluronic® 
F127 has a PPO:PEO ratio of 30:70 when L92 is 80:20. The third copolymer of choice 
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was poly(propylene glycol), a hydrophobic material with a molecular weight of 3500 
Da.(54) 
~~---..~~------~ . .--. 
X Y X 
PEO-PPO-PEO 
MW lkD-13kD 
x = 0 - 300 
y = 15 - 80 
Figure 10: Poly( ethylene oxide )-poly(propylene oxide) block copolymers or 
Pluronics® 
5.2. Microgel synthesis model and annotated structure 
The synthesis model has been studied extensively.(7, 9, 11) The synthesis 
sequence for micro gels involved free-radical polymerization of acrylic acid with chain 
transfer to block copolymer resulting in C-C bonding between P AA and Pluronic® . 
At 70°C, initiators form free radicals (R -) that trigger propagation of acrylic acid 
(AA) homo-polymer chains and abstraction ofhydrogen (H) from the block copolymers 
(XmH). Latter activation of block copolymers (Pluronics® and PPG 3500) leads to the 
chain transfer that is followed by grafting of P AA chains on block copolymers: 
R- + nAA ~ R-AAn-
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Introduction of di-vinyl crosslinker leads to formation of a PAA network, 
crosslinked by EGDMA, with grafted block copolymer chains. (Fig.ll) 
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Figure Il: Proposed structure of microgel fragment 
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5.3. pH responsive properties of microgels 
The microgels are responsive to environmental pH changes, which is crucial for 
protection of API from the acidity and proteolytic enzymes of gastric fluids. At low pH of the 
human stomach, the microgels stay collapsed and drug is not released, however, at pH closer to 
neutral, in the intestine, these materials start to swell and release active pharmaceutical 
ingredient.(11 ) 
5.4. Mucoadhesion of micro gels 
Among various possible bioadhesive polymeric hydrogels, P AA has been considered as a 
good mucoadhesive. It has been intensively studied and a number of mucoadhesive formulations 
was developed based on this polymer.(26, 37, 42) Polyether modified PAA formulations 
demonstrated mucoadhesive properties and are proven to be non-irritating.(6, 8, 10) 
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EXPERIMENTAL PART 
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Objectives: 
The general objective of this project is to synthesize and study micro gels of crosslinked 
poly(acrylic acid) network with grafted block-copolymers chains (poly(ethylene oxide)-
poly(propylene oxide) or poly(propylene glycol)) as a potential matrix for oral administration of 
therapeutic proteins and peptides. These microgels are synthesized in order to protect large 
, 
molecular size drugs in the stomach, and to pro vide prolonged release in the intestine. 
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1. MATERIALS AND METHODS 
1.1. Materials 
Name Lot Number Supplier 
Acetonitrile A25627 Aldrich 
Acrylic Acid mono mers (AAM) 10630LB Aldrich 
4' -4-azobis-( 4-cyanovaleric acid) 12688/1 Fluka 
Bovine Serum Albumin A 7906 113K0669 Sigma 
Carbopofw 971 NF CC9DAAJ085 Noveon 
Dichloromethane 99.9% LI00262KI Aldrich 
Dodecane DA027360A Aldrich 
Ethylene Glycol Dimethacrylate 07711LO Aldrich 
Ganex V-216 03200068154 ISP 
technologies 
Hexane 10655HC Aldrich 
Hydrochloric Acid IN standard 00507HC Aldrich 
Lactose 03912MC Sigma 
Lauroyl Peroxide 03727PO Sigma 
Magnesium Stearate 18724MA Aldrich 
Pluronic® F127 WPNX60C BASF 
Pluronic® L92 WPDX5335B BASF 
Poly(propylene glycol) 3500 08831AO Aldrich 
RS Protein Assay 81495A Bio-Rad 
Sodium Hydroxide 91040 MAT 
Sodium Hydroxide IN standard 03427DD Aldrich 
Sodium Phosphate dibasic anhydrous 85H0425 Sigma 
Sodium Phosphate monobasic mono hydrate 67H1245 Sigma 
Trifluoroacetic Acid 001210-50209- PSIG 
259 
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1.2. Equipment 
• Mechanical stirrer BDC 1850, Caframo 
• Hot plate with magnetic stirrer, Fisher Scientific 
• Filter paper 10Jlm, Whatman 
• Soxhlet extractor 
• Market grade test sieves mesh 20(0.86mm), 40(0.36mm) and 100(0. 14mm), Dual 
Manufacturing Co. 
• Optical microscope Labophot-2, Nikon 
• Tap density tester, Vanderkamp 
• Differentiai scanning calorimeter DSC-30, Mettler 
• Nuclear magnetic resonance spectrometer Avance 600 MHz, Bruker 
• Fourier transformed infrared spectrometer FTS800, Varian 
• Reversed-phase HPLC column 218TP54, Vydac 
• DuaI À absorbance detector 2487, Waters 
• HPLC sampler manager 2700, Waters 
• Binary HPLC pump 1525, Waters 
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• pH meter Orion 525A+, Thermo Electron 
• Tube rotator, Scientific Equipment Products 
• Hydraulic press, Carver 
• Punch and Die 0 1 cm, custom made 
• Tablet hardness tester PTB 302, Pharma Test 
• Balance BP211D, Sartorius 
• Incubator, Power Scientific 
• Variable-rate flask shaker, St. John Associates 
• Microcentrifuge Micromax, IEC 
37 
1.3. Methods 
1.3.1. Microgel synthesis 
The microgels were synthesized on laboratory scale according to the method (11) 
originally described by Dr. Lev Bromberg (Fig. 12) with sorne modifications. 
1.3.1.1. Preparation of Block Copolymer Solution (Solution A) 
39mL of AAM was neutralized by 0.5mL of 5M NaOH, charged into a flat-bottom 
flask and mixed. 24 g ofblock copolymer (Pluronic® or PPG 3500) and 1.1mL ofEGDMA was 
charged into the flask and ~ixed vigorously. The mixture of initiators: 100mg of Lauroyl 
peroxide and 100mg of 4' -4-azobis-( 4-cyanovaleric acid) in 2mL of AAM was added. The 
solution was stirred at 200rpm by magnetic stirrer for 10 minutes. AlI these operation were 
performed under a constant flow of dry nitrogen at room temperature. The mixture was 
deoxygenated for 30 minutes. 
1.3.1.2. EmulsionlDispersion 
A 500-mL three-necked round-bottom flask was charged with 250mL of 1 % w/v Ganex 
solution in dodecane and deoxygenated ovemight with constant stirring at 100rpm with a purge 
of dry nitrogen at room temperature. Next day, the flask was placed into an oil bath with 
temperature controller. The flask was equipped with a mechanical stirrer and a thermometer. 
Solution A was charged into the round-bottom flask. Dry nitrogen purge was initiated and kept 
until the end of the reaction. The mixture was stirred for 30 min at 200rpm at room 
temperature. Stirring rate was raised to 300rpm and maintained at this intensity until the end of 
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the reaction. Step-wise heating was started at the rate of 1-2°C per minute up to 70°C. The 
temperature was maintained at 70°C until the end of the reaction, for 4 hours. 
1.3.1.3. Filtration, Washing and Drying 
The reaction slurry was cooled to room temperature and filtered using Whatman filter 
paper (10Ilm). The wet filtrate was repeatedly washed with hexane and dried under vacuum 10-
3 Torr at room temperature for 36 hours. The dried microgel was then washed in a Soxhlet 
extractor with dichloromethane for 72 hours. AH the wash-out from both steps were collected 
and evaporated under vacuum to be used in the estimation of the effective degree of bonding 
between block copolymers and poly(acrylic acid). The washed micro gel was dried under a 
vacuum of 10-3 Torr at room temperature for 48 hours. 
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Figure 12: Microgel synthesis, washing and drying 
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1.3.2. Microgel composition determination 
1.3.2.1. Fourier transform infrared spectroscopy (FTIR) 
FT IR analysis was done using a Varian FTS800. Block copolymer samples were 
prepared in dichioromethane in seriaI dilutions and analyzed for characteristic peaks at a 
wavenumber of 1100. Dried synthesis washouts from aH the batches, reconstituted in 
dichloromethane were analysed by FTIR for the peak intensity at the respective wavenumber, 
and quantities of unbound block copolymers for each batch were estimated from standard 
curves. 
1.3.2.2. Estimation of effective degree of boding 
An effective degree ofbonding between block copolymers and poly(acrylic acid) was 
calculated for aIl three microgels according to the following equation: 
Where: 
. DoB 
DoB = (Pch - P,).100% / P ch (eq.12) 
effective degree ofbonding (%) 
initial weight ofblock copolymer charged into the reactor (mg) 
weight of block copolymer In washouts, not· hound during the 
synthesis (mg) 
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1.3.2.3. High-performance liquid chromatography (HPLC) 
An analytical HPLC system with reversed-phase column was equilibrated using 0.1 % 
(v/v) aqueous trifluoroacetic acid at a flow rate of 1mLlmin. A linear gradient of water (0.1 % 
TF A)/ Acetonitrile (0.1 % TF A) from 9: 1 (v/vI) to 3:7 (v/v) was used. SeriaI dilutions of 
AAMs were prepared in water. Samples were injected by an automatic autosampler and 
monitored at 225nm and 280nm by means of a dual Â Absorbance Detector. 
1.3.3. Microgel characterization 
1.3.3.1. DifferentiaI scanning calorimetry (DSC) 
DSC evaluation was performed on each batch of dry micro gel particles and aU 
starting materials: AAMs, Pluronic® F127, Pluronic® L92 and PPG 3500. AH samples were 
tested utilizing Mettler DSC 30in standard aluminum crucibles at heating rate of lOoK/min 
was applied to aH DSC samples. Scanning was performed under constant nitrogen flow and 
with the starting temperature not higher them -1 OooK. 
1.3.3.2. Solid 13C nuclear magnetic resonance (NMR) 
Samples from each batch ofF127, L92 and PPO Microgels and Pluronic® F127 were 
prepared in tubes for solid state NMR. 13C spectra were acquired on a Bruker Avance 
600 MHz spectrometer at 600 MHz by staff of the Department of Chemistry of the 
University of Montreal. 
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1.3.3.3. Swelling of microgels and pH titration studies 
Swelling experiments were performed on each batch of micro gel in duplicate. 
Samples of lcm3 of dry material, independent of weight, were placed into 50ml plastic 
measuring flat bottom cylinders. The cylinders were sealed with rubber stoppers thoroughly 
at all time. The study was done at 37°C. Samples were pre-swelled in 30ml of distilled water 
for 2 days. After pre-swelling, the pH of the slurry was lowered to 2.0. Then the pH was 
increased gradually adding O.4mL of NaOH standard solution. These steps were repeated 
until the pH reached 12.0 for each microgel except micro gel PPO, which swelled to· the 
maximum volume at pH 6.0. IN HCI and IN NaOH standard solutions were used t6 adjust 
the pH. AlI samples were alIowed to stand for a minimum of 3 ho urs after adding NaOH or 
HCI and then the height was measured 
The swelling ratio (S) was calculated as folIows: 
Where: 
Ho 
(eq. 13) 
height ofthe swelled microgel column during the experiment 
height of the microgel column at time "0" (1 ml of dry micro gel 
pre-swelled in distilled water) 
Microgel PPO titration continued after the point of maximum swelling at pH 6.0 up 
to pH 12.0. These results were normalized per gram of dry micro gel and plotted. 
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1.3.3.4. Particle size determination and imaging of dry microgel particles 
Particle size analysis was performed for dry micro gel particles using market grade 
test sieves with mesh 20(0.86mm), 40(0.36mm) and 100(0.14mm). The fractions were 
weighted by means of an electronic balance (±0.01 mg). Images of the dry particles were 
obtained using an optical microscope Labophot-2. 
1.3.3.5. Carr's compressibility index determination 
A Vanderkamp Tap density tester with a tapping frequency 150 taps per minute was 
used to determine Carr's compressibility index.(16, 17) The tared 250-mL measuring 
cylinder was filled with pre-weighted test material to 100 mL, then the initial (or bulk) 
density was estimated. With minimal disturbance of the measuring cylinder, it was 
transferred to the tap density apparatus, tapping was done 150 times then the final (or tap) 
density was estimated considering the reduced volume of the sample after tapping. 
The following equation was used to calculate Carr' s compressibility index (x): 
x= (Do-Dt) .100% / Do (eq.14) 
Where: 
Do initial (bulk) density (glcm3) 
Dt final (tap) density (g/cm3) 
44 
1.3.4. Microgel preparation and tabletting 
Dry blending was used to fonnulate both test and reference products. Series of dry 
blends were prepared for each batch of microgel in duplicate. F127 microgel, L92 microgel, 
PPO microgel, Carbopol and Lactose were dry blended with 2%, 10%, 20% or 50% w/w of 
protein (BSA) and 0.5% w/w of Magnesium Stearate as a compression lubricant. BSA was 
sieved through a series of market grade test sieves before blending and the fraction between 
meshes 40 (0.36mm) and 100(0.14mm) was selected. Blank blends without BSA were 
prepared for each batch as a negative control. Blending was carried out at room temperature 
in glass vials on vertical tube rotator at 10 rpm for twenty minutes. 
Flat-faced plain tablets weighting 300mg, having a thickness of 3mm and with a 
diameter of 10mm, were compressed on a Carver press with 5000kg force applied. 
1.3.5. Acidic fluids and phosphate buffer preparation 
Acidic fluids were prepared by lowering the pH of distilled water to 2.2 by adding 
Hel (lN) volumetric standard solution. The 0.5M phosphate buffer pH 6.8 was prepared as 
follow: 14.08g of sodium phosphate monobasic monohydrate and 13.92g of sodium 
phosphate dibasic anhydrous were dissolved in four litres of distilled water. The final pH was 
aqjusted to 6.8 if required. 
1.3.6. Dissolution method and protein assay 
The limited sensitivity of the protein assay did not allow using the standard USP 
dissolution apparatus. The dissolution tests were perfonned on synchronised flask shakers 
45 
placed into a temperature-controIled environment of an incubator. Sample tablets were 
placed into SOmL sealed plastic Falcon tubes. Tablets were tested at 37°C for 48 hours: two 
hours in SOmL of acidic fluids at pH2.2, then the solution was changed using the same 
volume of O.SM phosphate buffer pH 6.8 to mimic the GI tract conditions. During the acidic 
treatment samples and blanks were shaken at 15 rpm then, after the change to phosphate 
buffer shaking was increased to 100 rpm. Aliquots of O.3mL were taken at 0, 1, 2, 2.5, 3, 4, 
5,8,24 and 48 hours. The aliquots were compensated with the same volume of the phosphate 
buffer at the same temperature (37°C) at each measurement. Acidic aliquots were neutralized 
using NaOH IN standard solution as required for the protein assay taking in consideration 
the dilution factor. 
Bio-Rad RC protein assay was used to determine the concentration of BSA. AIl the 
aliquots were centrifuged using a microcentrifuge at 10,000 rpm for 10min prior the protein 
assay. Sampling of the supematant was done in order to avoid presence of microgel particles 
in the assay. Samples with a concentration higher then the assay range were diluted 
respectively. AlI aliquots were assayed in triplicates. The protein assay was carried out in 
accordance with the following standard operational protocol: 
1 Prepare 6 dilutions of a protein standard (BSA) containing from 0.2 mg/mL to 1.2 
mg/mL. A standard curve is prepared each time the assay is performed in triplicate 
and in the same buffer as the sample. 
2 Pipette 5 J.lL of standards or samples into a clean, dry microtiter plate. 
-3 Add 25 J.lL of reagent A into each weIl. 
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4 Add 200 flL of reagent B into each well. Place the plate on a microplate reader and let 
the plate mix for 5 seconds. 
5 After 15 minutes, read the absorbance at 750 nm. The absorbance is stable for about 1 
hour. 
1.3.7. Method of estimation of release kinetics parameters 
The Peppas equation was applied to determine the kinetic parameters of BSA 
dissolution.( 45) 
MIMex; =k.1' (eq.15) 
Where: 
degree of BSA release 
kandn kinetic parameters 
t time(hours) 
The estimation of the kinetic parameters "k" and "n" was performed by linear 
regression of the logarithmic values of the time and degree of BSA release using the linear 
form of Peppas equation: 
log (MIMŒJ)=log(k)+ n log(t) (eq.16) 
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2. RESULTS AND DISCUSSION 
2.1. Microgel synthesis 
Two consecutive batches of each micro gel were synthesized in accordance with the 
method described in the section 1.3.1 at laboratory scale in adiabatic mode by a one-step 
free-radical crosslinking copolymerization of acrylic acid monomers and block copolymers 
with the covalent crosslinker ethylene glycol dimethacrylate. Both batches of each material 
were used in subsequent experiments. 
2.2. Microgels composition determination 
Given that resulting microgels are solid and absolutely insoluble whereas key starting 
compounds are mostly liquid, it was not feasible to use the same analytical technique to 
determine the degree of bonding for block copolymers. Thus washouts from the synthesis 
were collected and analysed by FTIR and HPLC to determine the composition of the solid 
fraction. FTIR results for seriaI dilutions of block copolymers obtained by the method 
described in section l.3.2.1, are presented in Figure13 a. b and c 
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Figure 13: FT IR results for seriaI dilutions of Piuronic® FI27 (a), Piuronic® L92 (b) 
and PPG 3500 (c) in dichlorornethane 
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r - Areas under the curve for the characteristic peaks were plotted to obtain standard 
curves for respective material in order to quantitate these compounds (Fig. 14 a, b, c). 
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Figure 14: Standard curves for Pluronic® F127 (a), Pluronic® L92 (b) and PPG 3500 
(c) in dichloromethane 
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2.2.1. Block copolymer binding 
An effective degree ofbonding between block copolymers and poly(acrylic acid) was 
calculated for aIl three microgels in accordance with Equation 12. Quantitation of unbound 
block copolymers demonstrated a relatively high degree of bonding for these starting 
materials. More then 90% ofblock copolymers for both Pluronic®-based microgels and up to 
96% for PPO micro gel were not detected in the solvable washout of the synthesis. (Fig.15) 
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Figure 15: Block Copolymer incorporation into the microgels structure 
2.2.2. Acrylic acid monomer binding 
Acrylic acid concentration in seriaI dilutions and synthesis residuals was assayed by 
the HPLC method detailed in the section 1.3.2.3. HPLC results for seriaI dilutions of acrylic 
acid monomers are presented in the following figure. 
5mglmL 
Acrylic acid, by HPLC 
UO 1~ 1.70 1.7C5 1.EO 1.BC5 1.QO 1.Q!5 2.00 2.0C5 210 2.1C5 
"'lno.tes 
Figure 16: Acrylic acid monomer HPLC chromatograms used for calibration 
Figure 17 shows that acrylic acid mono mers were not detected in FI27 microgel 
wash-outs. Similar results were obtained for L92 and PPO microgels. High efficiency of 
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acrylic acid monomer incorporation into microgels has been previously reported.(12) Thus it 
was assumed that an the acrylic acid monomers charged into the reactor were consumed in 
the synthesis. 
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Figure 17: Acrylic acid mono mer were not detected by HPLC in F127 microgel wash-outs 
2.2.3. Efficacy of the microgel washing procedure 
DifferentiaI scanning calorimetry experiment was performed on dry particles of 
microgel according to the method described in section 1.3.3.1 to evaluate the completeness of 
the synthesis and to verify that they were free ofunbound phase after the multi-step washing-
drying procedure. Starting materials were assayed by DSC as references. Actual DSC data 
can be found in Appendix l of this memoir. 
Acrylic acid had demonstrated a sharp melting peak at 12°C, which was in 
compliance with the literature source.(22) This type of phase transition was not identified in 
any ofthe micro gel DSC profiles. 
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Pluronic® F127 distinctive melting peak at 56°C was in accordance with the technical 
bulletin of the manufacturer.(SO) No phase change occurred at this temperature in the 
Microgel F127 samples. 
According to the information provided by the BASF technical support staff, 
pour/melting point for liquid Pluronic® L92 is + 7°C. A small endotherrnic peak was observed 
at that temperature in pure block copolymer DSC profile. However no melting transition was 
identified at 7°C in Microgel L92. 
PPG-3500 is a liquid polymer. An endothermic peak was observed at -59°C. There 
was no heat flow event identified at temperatures lower then -50°C in PPO Microgel. 
The absence of the key starting material characteristic peaks in the DSC profiles for 
F127, L91 and PPO Microgels proved that the multi-step washing and drying procedure 
yielded materials of high purity. 
2.2.4. Microgel structure elucidation by solid 13e NMR 
Solid NMR technique, detailed in section 1.3.3.2, was selected due to the insoluble 
nature of the microgels. Only Pluronic® F127 among the key starting materials was solid, 
thus it was not feasible to perforrn a quantitive experiment. Carbon-13 NMR data was 
gathered in order to characterize the structure of the micro gels. The signaIs from carbon 
nuclear magnetic resonance spectrum were assigned (Fig. 18) to the carbons presented in the 
, 
molecule.(SS) Chemical shifts are listed in Table 2. 13C-NMR profiles for the microgels and 
Pluronic® F127 are presented in Appendix II. 
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Carbon-13 profiles of all of the microgels exhibited chemical shifts between 25 to 
44ppm and 177 to 179ppm, which are characteristic for carbon atoms of poly(acrylic acid) 
chains. Pluronic® F127 spectra demonstrated the chemical shifts typical for Carbons of 
block-copolyrners: at 18ppm, 61ppm, 70ppm and 74-78ppm. Those shifts were less 
distinctive in the microgel spectra, especially in the PPO Microgel sarnple; however in the 
most cornrnon l3C-NMR experiments the intensity of the signal is not directionally 
proportional to the number of equivalent l3C atoms.(5) NMR spectra of aIl the Microgels 
were consistent with their proposed structure. 
Figure 18: Annotated fragment of microgel structure 
55 
13C Chemical Shift (ppm) Assignment 
19 1 
25-48 2 
61 3 
70-71 4 
74-78 5 
177-179 6 
Table 2: Chemical shifts and assignments for 13C NMR 
2.2.5. Estimation of microgel composition 
Based on binding data for Pluronics®, PPG 3500 and acrylic acid monomers microgel 
compositions were estimated (Fig.l9 a, b, c). AU three microgels contain equivalent 
proportion ofpoly(acrylic acid) which is approximately equal to 65% and 35% by weight of 
block copolymer, however, for the latter the PEO-PPO ratio varies and defines the 
hydrophilic-hydrophobic properties of the microgels. 
a 
56 
L92 microgel 
b 
PPO microgel 
c 
Figure 19: Estimated Compositions of F127 microgel (a), L92 micro gel (b) and PPO 
microgel (c). 
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2.3. Characterization of microgel in aqueous milieu 
2.3.1. Swelling of microgels 
The swelling ratio was calculated in accordance with Equation 13 as described in 
section 1.3.3.3. Figure 20 shows that Microgel F127 swells the least at pH 12.00 compared 
to two other micro gels, while Microgel PPO swells the most at pH 6.0. Microgel L92 
demonstrated an intermediate swelling. 
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Figure 20: Swelling profiles of the micro gels 
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These results were compared to the estimated compositions of the microgels: aIl three 
of them contain 64-65% weight content of P AA and vary in the grafted block-copolymer 
proportion. (Fig. 21) Thus the most hydrophobic material, Microgel PPO, demonstrated the 
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highest degree of swelling followed by the moderately hydrophilic Microgel L92. Microgel 
F 127 swelled the least and was estimated to be the least hydrophobic due to composition of 
Pluronic® F127. 
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Figure 21: Microgels relative Hydrophobic and Hydrophilic Blocks composition 
2.3.2. Titration of microgels 
Titration was carried out in accordance with the method detailed in section 1.3.3.3. 
The results were nonnalized per gram of dry micro gel and plotted. It was observed that aIl 
three microgels required approximately equal molar amount of Sodium Hydroxide per 1 
gram of dry Microgel to neutralize the carboxyl groups. Quantitation was made to estimate 
an isoelectric point at 0.008 moles of NaOH, hence straightforward calculation resulted with 
roughly 580 mg of P AA per 1 gram of a micro gel. That did not precisely correlate with the 
previously estimated 65% of weight however this may be explained by the reduced 
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accessibility of 5 to 10 % of the micro gel P AA chains within the microgel structure. AlI three 
Microgels responded similarly during the titration. 
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Figure 22: Microgels pH titration results were normalized per gram of dry microgel. 
2.4. CharacterÏZation of dry microgel particles 
2.4.1. Particle sÏZe determination 
Particle size distribution for each batch of microgel was done using a series of market 
grade test sieves (Fig.23) as described in section 1.3.3.4. The main fraction for both 
microgels based on Pluronics® was the one between meshes 40 (0.36mm) and 1 00(0. l4mm) 
as for the PPO microgel it was between meshes 40 and 100 and between meshes 100 and 
200(0.074mm) in about equal amounts. Thus, fraction between meshes 40 and 10 was chosen 
for farther experiments. 
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Figure 23: Microgel particles size distribution. 
2.4.2. Dry particles morphology 
0.074 
• PPO microgel 
• L..92 microgel 
[] F127 microgel 
The morphology of dry microgel particles was studied by optical microscopy. F127 
micro gel particles are of regular spherical shape of 100-180 Ilm diameters with a smooth 
surface, Image la. L92 microgel had similar shape and size, however, the surface of the 
particles was rougher and may be characterised by sorne sponginess, Image 1 b. This is 
similar to the results demonstrated by Dr. L.Bromberg (12). The higher susceptibility of the 
PPO content of Pluronics® to hydrogen abstraction reaction compared to PEO fragments was 
previously described.(9) This might lead to fonnation during the synthesis of highly 
crosslinked PPO-rich domains, which are later integrated into particles with less regular 
shape. The PPO content is almost twice higher in Pluronic®L92 then in Pluronic®F127. It 
also corresponds to the results for PPO microgel which is a material of highly dispersed size 
and shape, Image lc, probably due to the very high degree of crosslinking. 
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r 
62 
c 
Image 1: a) microgel F127; b) microgel L92; c) microgel PPO 
2.4.3. Carr's compressibiIity index 
Carr' s compressibility index was calculated in accordance with Equation 14 for each 
microgel (Fig.24) as described in section 1.3.3.5. The best results, close to 20%, were 
obtained for both Pluronic based microgels. This characterised F127 microgel and L92 
microgel as products with good flowability and low cohesiveness, which are important 
characteristics for direct compression.(16, 17) 
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Carrls Compressibility Index 
Lactose 
Carbopol 42% 
Microgel PPO 
Microgel L92 
Microgel F127 
Figure 24: Carr's compressibility index for microgels F127, L92 and PPO microgels 
vs. two commonly used excipients: lactose (immediate release) and Carbopol (modified 
release) 
2.5. Microgelloading capacity 
The drug loading capacity of micro gels was studied in order to frnd the optimal 
microgel-to-protein ratio. Series of dry blends were prepared for this purpose for each batch 
of gel, in duplicate, according to the process detailed in section 1.3.4 with a protein content 
of 2%, 10%, 20%, and 50% w/w. Hence, the final formulation inc1uded respective amount of 
BSA, dry microgel and 0.5% w/w of Magnesium Stearate as a lubricant. 
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2.5.1. Effect of loading on protein release 
Conditions mimicking the gastrointestinal tract were applied to the sampi es during 
protein release experiments. Buffer preparation, dissolution method and protein assay 
procedure were described in section 1.3.5 and 1.3.6. As shown in Figure 25, the optimal 
results were obtained for a 10% BSA blend. The protein released during the acidic fluid 
treatment was negligible. Subsequently BSA was released at moderate and near constant rate 
in the neutral milieu. Microgel formulations with 2% BSA loading did not provide detectible 
release for more than 3 hours of dissolution test and then released aIl the loaded prote in 
within 2 hours. Formulations with a protein loading higher then 10% did not efficiently 
prote ct active ingredient during the acidic treatment due to high porosity. 
Both Pluronic® based microgels released up to 98% of loaded BSA. However, for 
PPO microgel the maximum release was only 80% for formulation with 50% of loaded 
protein. The average error did not exceed 7% for aIl the results. 
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Figure 25: F127 (a), L92 (b) and PPO (c) Microgels Loading Capacity: protein 
release from seriai microgel fonnulations 
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2.6. Protein release from the microgels at 10% loading 
Formulations with 10% prote in w/w were prepared by dry blending as described in 
the section 1.3.4 for aH three microgels, lactose and Carbopol. Tablets were compressed to 
the same dimensions and weight as for previous experiment. Dissolution test and prote in 
assay were carried out in accordance with the same procedure as for the microge1 loading 
capacity evaluation experiment. Lactose and Carbopol were used as immediate and modified 
release reference excipients respectively. Plotled experiment results are provided in Figure 
26. 
Lactose tablets were dissolved during the acidic fluid treatment, which is expected in 
an immediate release formulation, whereas Carbopol did not release protein even up to 30% 
10ading after 48 hours of experiment while Pluronic® based microgels demonstrated the best 
protein release profiles. The average error did not exceed 6% for aH the results. 
Results of BSA release from the micro gels presented in 2D chart form are in Figure 
27. AH three micro gels provided an efficient protection for the prote in at lower pH's during 
the 2 hours of acid fluids treatment, Figure 28. However the PPO micro gel only released up 
to 72% ofloaded BSA after 46 hours oftreatment at neutral pH. 
Microgels F127 and L92 provided prolonged release of BSA fomp to 99% of the 
loaded protein. About 70% and 50% of loaded BSA was released from Microgel F127 and 
L92 respectively after 2 ho urs of neutral buffer treatment.' Over 90% of BSA was released . 
from the both microgels after 6 hours of swelling in phosphate buffer pH6.8. 
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Figure 26: Microgels protein release profiles ofvs. Carbopol and Lactose formulations 
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Figure 27: BSA release from the microgels: first 2 hours samples were treated with acidic 
fluids at pH 2.2, after that solution was changed for O.5M phosphate buffer pH 6.8 
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Figure 28: BSA release from the microgels after 2 ho urs of treatment with acidic fluids at 
pH 2.2 
2.7. Kinetics study of proteio release 
The Peppas model (31, 44) was used to determine the type of the release mechanism 
in accordance with the calculation method presented in the section 1.3.7. Linear regression 
on logarithmic values of the time and degree of BSA release in accordance with Equation 16 
was performed in order to estimate the kinetic parameters "k" and "n".(Fig. 29) 
Both kinetic parameters for aIl tree microgels were estimated. Table 3 shows that the 
order "0" of BSA dissolution varied between 0.63 to 0.98, which corresponds to a non-
Fickian or anomalous mechanism of diffusion. 
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Figure 29: BSA release from the microgels: log-log representation 
Microgel Kinetic Parameters (Peppas model) 
k n 
FI27 28.40 0.63 
L92 12.67 0.98 
PPo 7.40 0.90 
Table 3: Kinetic parameters of prote in release from the microgels 
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3. CONCLUSION 
This study demonstrated that microgels: copolymers of poly(acrylic acid) network 
crosslinked with ethylene glycol dimethacrylate with grafted· poly(ethylene oxide)-
poly(propylene oxide) block copolymer (Pluronic~ chains, have potential as release 
matrices for oral administration of therapeutic proteins and peptides. Pluronic® based 
microgels formulations protect the active pharmaceutical ingredient from the low pH of 
stomach fluids at the temperature close to human body for 2 hours, and pro vide prolonged 
release at neutral pH of the intestine for more than 6 hours. 
Microgels were synthesized by a one-step free-radical crosslinking copolymerization 
on a laboratory scale and thoroughly washed with organic solvents and dried. DSC results for 
aIl three microgels showed that multi-step washing and drying procedure yielded materials 
with high purity. 
DSC results of micro gels vs. key starting materials confirmed that synthesis of aIl 
three excipients was complete as no presence of the starting materials was identified in any 
micro gel sample. DSC results demonstrated that micro gels are thermo-stable within the range 
from DOC to 15D°C. Solid state l3C nuclear magnetic resonance spectra of the microgels were 
consistent with their proposed structure. 
Microgel compositions were estimated based on the quantitation of washed-out, 
unreacted ,starting materials. It was found that each micro gel contained 65% of poly( acrylic 
acid) and 35% of block copolymer on average. Titration of the materials with sodium 
hydroxide confirmed an equal poly(acrylic acid) contents in the microgels. 
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Pluronic®-based dry micro gel particles were of regular spherical shape of 100-180 
Ilm diameters with a relatively smooth surface. The micro gels have good flowability and low 
cohesiveness. These characteristics are valuable considering the relatively uncomplicated dry 
blending formulation of the final drug product. 
Swelling studies have shown that PPO Microgel are highly swellable at neutral pH. 
However, protein release from this material was not satisfactory, almost 30% ofloaded BSA 
was not released after 46 hours of swelling in phosphate buffer at pH6.8, and thus this 
material is not considered to be an excipient of choice for protein-based active 
pharmaceutical ingredients. 
Both Pluronic®-based Microgels swelled in response to a pH increase: while being 
collapsed at pH lower then 3.0, they increased in volume between pH 4.0 and 8.0. After pH 
8.0 Microgel F127 did not show significant swelling while Microgel 192 swelling gradually 
increased up to the final point of the experiment pH12.0. BSA release results on the contrary 
showed that Microgel F127 released 'protein faster then Microgel L92. These micro gels 
provided 7 hour release ofprotein at neutral pH ofup to 98% ofloaded BSA, which were the 
best results compared to 70% released from PPO micro gel and less the 30% from Carbopol. 
Both ofthese observations, swelling and BSA release profile, might be co-dependent. 
The micro gel with higher hydrophilic content swelled less and allowed faster diffusion while 
the increase in the hydrophobic degree of microgels slowed the release and might have a 
negative effect on total amount of the protein released. Kinetics study showed that the 
mechanism ofBSA diffusion from the Microgels F127 and L92 was non-Fickian. 
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Appendix 1 
DSC SPECTRA 
For 
Acrylic acid monomers, 
Pluronic@ F127, 
F127 microgel, 
Pluronic@ L92, 
L92 microgel, 
Poly(propylene glycol) 3500 and 
PPO microgel 
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Appendix II 
13C-NMR SPECTRA 
For 
F127 microgel, 
L92 microgel, 
PPO micro gel and 
Pluronic® F127 
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Image 1. 13C NMR Microgel PPO batch 1 
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Image 7. Be NMR Pluronic® F127 
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